for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Resverlogix Corp.

RVX.TO

Latest Trade

1.13CAD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.34

 - 

4.94

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Resverlogix Announces Topline Results In Betonmace Phase 3 Epigenetics Trial

Sept 30 (Reuters) - Resverlogix Corp <RVX.TO>::RESVERLOGIX ANNOUNCES TOPLINE RESULTS IN BETONMACE PHASE 3 EPIGENETICS TRIAL.RESVERLOGIX CORP - BETONMACE DID NOT MEET PRIMARY ENDPOINT.RESVERLOGIX CORP - BETONMACE DID NOT MEET PRIMARY ENDPOINT.RESVERLOGIX CORP - FULL STUDY RESULTS WILL BE PRESENTED DURING A LATE-BREAKING SCIENCE SESSION AT AHA 2019.RESVERLOGIX CORP - APABETALONE DEMONSTRATED TOLERABILITY AND SAFETY.RESVERLOGIX CORP - APABETALONE DEVELOPMENT TO CONTINUE TO BE ADVANCED BY COMPANY BASED ON BETONMACE RESULTS.

Resverlogix Provides Update On Betonmace Phase 3 Trial

Sept 16 (Reuters) - Resverlogix Corp <RVX.TO>::RESVERLOGIX PROVIDES UPDATE ON BETONMACE PHASE 3 TRIAL.RESVERLOGIX CORP - FOLLOWING DATABASE LOCK, BETONMACE TOP-LINE DATA IS EXPECTED TO BE ANNOUNCED ON OR ABOUT SEPTEMBER 30, 2019.RESVERLOGIX CORP - RESOLUTION OF ALL OUTSTANDING QUERIES EXPECTED WITHIN DAYS, LEADING TO DATABASE LOCK.RESVERLOGIX CORP - ENTERED INTO AN AMENDING AGREEMENT WITH THIRD EYE TO EXTEND MATURITY DATE OF CO'S SENIOR SECURED TERM LOAN FROM SEPT 16 TO SEPT 27.RESVERLOGIX CORP - PROJECTS NUMBER OF NARROWLY-DEFINED MACE TO BE USED IN PRIMARY DATA ANALYSIS NOW ESTIMATED TO BE GREATER THAN 275.RESVERLOGIX CORP - IN CONNECTION WITH AMENDMENT, RESVERLOGIX PAID AN AMENDMENT FEE OF $50,000.

Eastern Capital Exercised Warrants To Acquire 5 Mln Shares Of Resverlogix At Cash Price Of C$0.75/Share, For Total Consideration Of C$3.75 Mln

Aug 12 (Reuters) - Resverlogix Corp <RVX.TO>::EASTERN CAPITAL - EXERCISED WARRANTS TO ACQUIRE 5 MILLION SHARES OF RESVERLOGIX AT CASH PRICE OF C$0.75/SHARE, FOR TOTAL CONSIDERATION OF C$3.75 MILLION.

Resverlogix Announces Pricing Of Unit Offering

May 15 (Reuters) - Resverlogix Corp <RVX.TO>::RESVERLOGIX ANNOUNCES PRICING OF UNIT OFFERING.RESVERLOGIX CORP - PRICED ITS PREVIOUSLY ANNOUNCED MARKETED OFFERING OF UNITS OF COMPANY AT $4.00 PER UNIT.RESVERLOGIX CORP - EACH UNIT CONSISTS OF ONE COMMON SHARE AND ONE COMMON SHARE PURCHASE WARRANT.

Resverlogix Announces 3-Month Loan Extension

May 2 (Reuters) - Resverlogix Corp <RVX.TO>::RESVERLOGIX ANNOUNCES 3-MONTH LOAN EXTENSION.RESVERLOGIX CORP - ENTERED INTO AN AMENDING AGREEMENT WITH THIRD EYE CAPITAL.RESVERLOGIX CORP - AMENDMENT EXTENDS MATURITY DATE OF COMPANY'S SENIOR SECURED TERM LOAN BY THREE MONTHS TO AUGUST 4.RESVERLOGIX CORP - LENDERS AGREED TO REDUCE MINIMUM CASH BALANCE THAT COMPANY IS REQUIRED TO MAINTAIN FROM US$5 MILLION TO US$3 MILLION.

Resverlogix's Betonmace Phase 3 Trial Reaches Its Targeted 250 Major Adverse Cardiac Events

April 18 (Reuters) - Resverlogix Corp <RVX.TO>::RESVERLOGIX'S BETONMACE PHASE 3 TRIAL SUCCESSFULLY REACHES ITS TARGETED 250 MACE EVENTS.RESVERLOGIX CORP - BETONMACE EVENT-BASED, PHASE 3 REGISTRATION TRIAL HAS SUCCESSFULLY REACHED 250 PROJECTED MAJOR ADVERSE CARDIAC EVENTS.RESVERLOGIX CORP - SUCCESSFUL DATA FROM TRIAL WOULD ENABLE RESVERLOGIX TO PROCEED TOWARDS REGULATORY APPROVAL.

Resverlogix Gets Positive DSMB Recommendation For Phase 3 Study Of Apabetalone

March 27 (Reuters) - Resverlogix Corp <RVX.TO>::RESVERLOGIX ANNOUNCES NINTH POSITIVE DATA SAFETY MONITORING BOARD RECOMMENDATION FOR PHASE 3 STUDY OF APABETALONE.RESVERLOGIX CORP - DSMB REVIEWED AVAILABLE SAFETY DATA AND COMMENTED THAT NO SAFETY CONCERNS WERE IDENTIFIED.RESVERLOGIX CORP - BETONMACE TRIAL IS CURRENTLY EXPECTED TO BE COMPLETED WITHIN FIRST HALF OF CALENDAR 2019.

Resverlogix - Seventh Positive Recommendation From Data Safety Monitoring Board For Study Of Apabetalone

Aug 7 (Reuters) - Resverlogix Corp <RVX.TO>::RESVERLOGIX ANNOUNCES SEVENTH POSITIVE RECOMMENDATION FROM THE DATA SAFETY MONITORING BOARD FOR PHASE 3 STUDY OF APABETALONE.RESVERLOGIX - DSMB NOTED NO SAFETY/EFFICACY CONCERNS IDENTIFIED, TO CONDUCT ADDITIONAL PERIODIC REVIEWS FOR PHASE 3 STUDY OF APABETALONE.

Resverlogix Says Intends To Pursue U.S. Listing

July 31 (Reuters) - Resverlogix Corp <RVX.TO>::RESVERLOGIX INTENDS TO PURSUE U.S. LISTING.RESVERLOGIX - INTENDS TO REQUEST SHAREHOLDER APPROVAL FOR CONSOLIDATION OF CO'S COMMON SHARES AT ANNUAL & SPECIAL MEETING OF SHAREHOLDERS OF CO.RESVERLOGIX CORP - COMPANY'S COMMON SHARES AND WARRANTS WOULD CONTINUE TO BE LISTED ON TORONTO STOCK EXCHANGE.

Resverlogix Announces FDA Confirmation Regarding Filing Pathway For Apabetalone

June 14 (Reuters) - Resverlogix Corp <RVX.TO>::RESVERLOGIX ANNOUNCES FDA CONFIRMATION REGARDING FILING PATHWAY FOR APABETALONE.RESVERLOGIX - RECEIVED CONFIRMATION FROM FDA THAT BETONMACE, CO'S ON-GOING PHASE 3 STUDY, IF SUCCESSFUL, IS LIKELY TO SUPPORT FILING & NDA APPROVAL.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up